Reply - 04/08/18
| Disclosure of potential conflict of interest: J. E. Gern reports grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases during the conduct of the study; personal fees from PREP Biopharm Inc, Regeneron, and MedImmune, and other fees from Meissa Vaccines Inc, outside the submitted work; in addition, J. E. Gern has a patent Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines pending, and a patent Adapted Rhinovirus C pending. M. C. Altman has no relevant conflicts of interest. |
Vol 142 - N° 2
P. 713 - août 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

